They need to secure funding by way of partner or venture capitalist. There's still costly trials ahead and it's all up to Tierney to find the best way to continue on without too much dilution.
We have to see what Tierney is going to work out. There's still a lot of buzz around BioPharmX product development and so there is definitely value in what they have created and what they are working on.
Risk vs Reward! Understanding the cost of these trials and development can give you an understanding of why these type of companies sell off in the hundreds of millions. The question here is, how much is BioPharmX and their delivery system worth? Once you have a guess on that figure, divide it by the outstanding shares and now you have an idea of a reachable share price if a buyout occurred.
Where the price is sitting now and for those holding a low average, it would be a fantastic rate of return on your investment! That's why I'm here! Risk vs Reward!
News 
Market Data 
Discover 
